A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants

Condition:   Prostatic Neoplasms Interventions:   Radiation: Radiotherapy;   Drug: LHRHa;   Drug: Apalutamide Sponsor:   Janssen-Cilag Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials